BlossomHill Therapeutics (NASDAQ:BLSM) Shares Gap Up – What’s Next?

BlossomHill Therapeutics, Inc. (NASDAQ:BLSM) shares gapped up before the market opened on Tuesday. The stock had previously closed at $19.75, but opened at $21.17. BlossomHill Therapeutics shares last traded at $21.27, with a volume of 10,184 shares changing hands.

Wall Street Analysts Forecast Growth

BLSM has been the subject of a number of research reports. Zacks Research upgraded shares of BlossomHill Therapeutics to a “hold” rating in a research note on Wednesday, September 2nd. HC Wainwright started coverage on BlossomHill Therapeutics in a research report on Tuesday, September 1st. They issued a “buy” rating and a $35.00 target price on the stock. Wall Street Zen upgraded BlossomHill Therapeutics to a “hold” rating in a research note on Saturday, August 15th. JPMorgan Chase & Co. initiated coverage on shares of BlossomHill Therapeutics in a research report on Tuesday, September 1st. They set an “overweight” rating and a $28.00 target price for the company. Finally, Lifesci Capital started coverage on shares of BlossomHill Therapeutics in a research report on Tuesday, September 1st. They issued an “outperform” rating and a $32.00 price target on the stock. Five analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $35.00.

BlossomHill Therapeutics Price Performance

BlossomHill Therapeutics (NASDAQ:BLSM) last released its earnings results on Friday, September 18th. The company reported ($8.75) EPS for the quarter, missing analysts’ consensus estimates of ($0.84) by ($7.91). Analysts expect that BlossomHill Therapeutics, Inc. will post -5.54 EPS for the current year.

Insider Activity at BlossomHill Therapeutics

In other BlossomHill Therapeutics news, Director Carl Gordon purchased 625,000 shares of the business’s stock in a transaction on Monday, August 10th. The stock was acquired at an average price of $16.00 per share, for a total transaction of $10,000,000.00. Following the purchase, the director owned 2,714,279 shares of the company’s stock, valued at approximately $43,428,464. This represents a 29.91% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, General Counsel Vincent Liptak acquired 2,500 shares of the stock in a transaction dated Friday, August 7th. The stock was acquired at an average price of $15.80 per share, for a total transaction of $39,500.00. Following the completion of the transaction, the general counsel directly owned 109,212 shares of the company’s stock, valued at approximately $1,725,549.60. This represents a 2.34% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have bought 1,573,900 shares of company stock worth $25,181,900 in the last 90 days.

About BlossomHill Therapeutics

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.